ImmunityBio posts Q2 2026 revenue of $50.7 million as ANKTIVA pipeline advances

ImmunityBio reported second-quarter 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, which the company said marked the eighth consecutive quarter of sequential revenue growth since ANKTIVA's commercial launch.¹ First-half 2026 net product revenue reached $94.8 million, up 121% compared with the first-half of 2025, building on full-year 2025 net product revenue of $113.0 million.¹

On the regulatory side, in July 2026 the Emirates Drug Establishment of the United Arab Emirates granted marketing authorization for ANKTIVA covering BCG-unresponsive NMIBC for both CIS and papillary disease as well as metastatic NSCLC.¹ In the U.S., the FDA accepted for review a supplemental Biologics License Application for ANKTIVA plus BCG in patients with BCG-unresponsive NMIBC with papillary disease but without CIS, and set a target action date under PDUFA of January 6, 2027.¹ The company also said it plans a 2026 sBLA submission tied to the Phase 2B QUILT-2.005 trial in BCG-naïve NMIBC carcinoma in situ, with or without papillary disease.¹

On supply, ImmunityBio signed an exclusive development and supply agreement with Japan BCG Laboratory, giving it exclusive U.S. rights to develop, import, and commercialize an intravesical BCG product known as Tokyo-172, intended to support long-term BCG supply for NMIBC patients.¹

ANKTIVA is now approved or authorized in five regulatory jurisdictions, expanding its global footprint to 34 countries.¹

On finances, the company reported $357.4 million in cash and cash equivalents, and marketable securities as of June 30, 2026.¹ CEO Richard Adcock said "we are well-positioned to support both our commercial and clinical priorities" with that cash balance.¹